A new standard for relapsed or refractory follicular lymphoma
Mené sur 548 patients atteints d'un lymphome folliculaire récidivant ou réfractaire, cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du tafasitamab (un anticorps monoclonal ciblant CD19) à un traitement combinant lénalidomide et rituximab
Despite progress since 2020, including the approval of immunotherapy as third-line treatment, relapsed or refractory follicular lymphoma remains a clinical challenge, particularly among patients with early progression or resistance to anti-CD20-based regimens. Although the combination of lenalidomide and rituximab is a well established, chemotherapy-free option endorsed by international guidelines, outcomes remain suboptimal in high-risk populations, underscoring the need for novel therapeutic strategies
The Lancet , commentaire, 2025